journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/30407504/identification-and-validation-of-novel-microenvironment-based-immune-molecular-subgroups-of-head-and-neck-squamous-cell-carcinoma-implications-for-immunotherapy
#1
Y-P Chen, Y-Q Wang, J-W Lv, Y-Q Li, M L K Chua, Q-T Le, N Lee, A Dimitrios Colevas, T Seiwert, D N Hayes, N Riaz, J B Vermorken, B O'Sullivan, Q-M He, X-J Yang, L-L Tang, Y-P Mao, Y Sun, N Liu, J Ma
Background: Targeting the immune checkpoint pathway has demonstrated anti-tumor cytotoxicity in treatment-refractory head and neck squamous cell carcinoma (HNSC). To understand the molecular mechanisms underpinning its anti-tumor response, we characterized the immune landscape of HNSC by their tumor and stromal compartments to identify novel immune molecular subgroups. Patients and methods: A training cohort of 522 HNSC samples from the Cancer Genome Atlas profiled by RNA sequencing was analyzed...
November 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395162/non-inferiority-for-short-her-or-short-chemotherapy
#2
B Y Aktas, D C Guven, O Dizdar
No abstract text is available yet for this article.
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395159/quantitative-lymph-node-burden-as-a-very-high-risk-factor-identifying-head-and-neck-cancer-patients-benefiting-from-post-operative-chemoradiation
#3
Z S Zumsteg, M Luu, S Kim, M Tighiouart, A Mita, K S Scher, D P Lu, S L Shiao, J Mallen-St Clair, A S Ho
Background: Adjuvant chemoradiation (CRT) is standard for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery. However, emerging evidence suggests the number of positive lymph nodes (LNs) is the dominant determinant of survival in non-oropharyngeal HNSCC, and thus may better identify those benefiting from treatment intensification. Patients and methods: Patients from the National Cancer Database diagnosed with non-oropharyngeal HNSCC (oral cavity, larynx, hypopharynx) between 2004-2014 and undergoing surgical resection, neck dissection, and postoperative radiotherapy (RT) were included...
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395156/letter-to-the-editor
#4
M J Maurer, T M Habermann
No abstract text is available yet for this article.
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395155/development-of-tumor-mutation-burden-as-an-immunotherapy-biomarker-utility-for-the-oncology-clinic
#5
Timothy A Chan, Mark Yarchoan, Elizabeth Jaffee, Charles Swanton, Sergio A Quezada, Albrecht Stenzinger, Solange Peters
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive response rates and durable disease remission but only in a subset of patients with cancer. Expression of PD-L1 has demonstrated utility in selecting patients for response to ICB and has proven to be an important biomarker for patient selection...
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395152/carboplatin-in-the-neoadjuvant-treatment-of-triple-negative-breast-cancer-ready-for-prime-time
#6
T Foukakis
No abstract text is available yet for this article.
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30395144/pilot-randomized-trial-of-an-electronic-symptom-monitoring-intervention-for-hospitalized-patients-with-cancer
#7
R D Nipp, A El-Jawahri, M Ruddy, C Fuh, B Temel, S M D'Arpino, B J Cashavelly, V A Jackson, D P Ryan, E P Hochberg, J A Greer, J S Temel
Background: Hospitalized patients with cancer experience a high symptom burden, which is associated with poor health outcomes and increased healthcare utilization. However, studies investigating symptom monitoring interventions in this population are lacking. We conducted a pilot randomized trial to assess the feasibility and preliminary efficacy of a symptom monitoring intervention to improve symptom management in hospitalized patients with advanced cancer. Patients and Methods: We randomly assigned patients with advanced cancer who were admitted to the inpatient oncology service to a symptom monitoring intervention or usual care...
November 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30371735/genomewide-copy-number-alteration-screening-of-circulating-plasma-dna-potential-for-the-detection-of-incipient-tumors
#8
L Lenaerts, P Vandenberghe, N Brison, H Che, M Neofytou, M Verheecke, L Leemans, C Maggen, B Dewaele, L Dehaspe, S Vanderschueren, D Dierickx, V Vandecaveye, F Amant, J R Vermeesch
Background: Early cancer diagnosis might improve survival rates. As circulating tumor(ctDNA) carries cancer-specific modifications, it has great potential as a non-invasive biomarker for detection of incipient tumors. Patients and methods. We collected cfDNA samples of 1002 elderly without a prior malignancy, performed whole genome massive parallel sequencing and scrutinized the mapped sequences for the presence of (sub)chromosomal copy number alterations (CNAs) predictive for a malignancy...
October 29, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30364941/progression-free-survival-at-24-months-pfs24-and-subsequent-outcome-for-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-in-the-real-world-setting
#9
H T van der Galiën, M Hoogendoorn, R E Kibbelaar, T van Meerten, R S van Rijn
No abstract text is available yet for this article.
October 26, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30364934/activity-of-egfr-antibody-in-non-v600-braf-mutant-metastatic-colorectal-cancer
#10
Yucai Wang, Jeremy C Jones, Benjamine R Kipp, Axel Grothey
No abstract text is available yet for this article.
October 26, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30358824/medical-oncologists-must-get-more-involved-in-systemic-treatment-of-hepatocellular-carcinoma
#11
J L Raoul, S Faivre, J S Frenel, L Rimassa
No abstract text is available yet for this article.
October 25, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30358823/treatable-causes-of-diarrhoea-in-patients-on-tyrosine-kinase-inhibitors-for-metastatic-renal-cell-carcinoma
#12
S V Lightowlers, B Greef, T Eisen, A Matakidou, K Fife, E A Cameron
No abstract text is available yet for this article.
October 25, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30357394/an-adaptive-population-enrichment-phase-3-trial-of-trc105-and-pazopanib-versus-pazopanib-alone-in-patients-with-advanced-angiosarcoma-tappas-trial
#13
C R Mehta, L Liu, C Theuer
Background: Major challenges in clinical trials of ultra orphan oncology diseases include limited patient availability and paucity of reliable prior data for estimating the treatment effect and, therefore, determining optimal sample size. Angiosarcoma (AS), a particularly aggressive form of soft tissue sarcoma with an incidence of about 2,000 cases per year in the United States and Europe is poorly addressed by current systemic therapies. Pazopanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) is approved for the treatment of AS, with modest benefit...
October 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30357315/can-estrogen-receptor-status-predict-for-shorter-duration-of-adjuvant-trastuzumab-in-early-stage-breast-cancer
#14
Aju Mathew, Sebhat Erqou
No abstract text is available yet for this article.
October 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30357310/dose-tailoring-of-adjuvant-chemotherapy-for-breast-cancer-based-on-hematologic-toxicities-further-results-from-the-prospective-panther-study-with-focus-on-obese-patients
#15
A Matikas, T Foukakis, V Moebus, R Greil, N O Bengtsson, G G Steger, M Untch, H Johansson, M Hellström, P Malmström, M Gnant, S Loibl, J Bergh
Background: Adjuvant chemotherapy (ACT) for breast cancer improves relapse free (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surface area. Consequently, tailored dosing was prospectively evaluated in the PANTHER trial. Patients and methods: PANTHER is a multicenter, open-label, randomized phase III trial which compared tailored, dose dense epirubicin/cyclophosphamide (EC) and docetaxel (D) (tDD) with standard interval 5-fluorouracil/E/C and D...
October 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30357308/duration-of-adjuvant-trastuzumab-might-less-be-more
#16
Otto Metzger Filho, Harold J Burstein
No abstract text is available yet for this article.
October 24, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30351400/passion-for-immune-checkpoint-blockade-in-triple-negative-breast-cancer-comment-on-the-impassion130-study
#17
Marleen Kok, Eric Winer, Sherene Loi
No abstract text is available yet for this article.
October 23, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30351341/activity-of-the-hsp90-inhibitor-luminespib-among-non-small-cell-lung-cancers-harboring-egfr-exon-20-insertions
#18
Z Piotrowska, D B Costa, G R Oxnard, M Huberman, J F Gainor, I T Lennes, A Muzikansky, A T Shaw, C G Azzoli, R S Heist, L V Sequist
Background: There are currently no approved targeted therapies for NSCLC patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR mutations which are generally refractory to 1st/2nd generation EGFR inhibitors. We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20. Patients and Methods: 29 patients with stage IV NSCLC with EGFR ins20 identified on local testing and at least one prior therapy were enrolled on the trial between 8/2013 and 10/2016...
October 23, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30346479/leptomeningeal-tumor-response-to-combined-mapk-erk-inhibition-in-v600e-mutated-gliomas-despite-undetectable-csf-drug-levels
#19
A F Hottinger, D Bensaid, R De Micheli, B Moura, K Mokhtari, E Cardoso, A Idbaih, R Stupp
No abstract text is available yet for this article.
October 22, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30346470/editorial-on-interpretation-of-time-to-event-outcomes-in-randomized-trials-an-online-randomized-experiment-by-i-r-weir-et-al
#20
E D Saad, I F Tannock
No abstract text is available yet for this article.
October 22, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"